BeiGene Gears Up For Cancer Immunology Debut
This article was originally published in PharmAsia News
Executive Summary
After entering three drug candidates to clinical stage, securing first round financing and obtaining milestone payments from Merck Serono, BeiGene has eyed unveiling a cancer immunology pipeline and a potential listing on the NASDAQ.
You may also be interested in...
Pfizer Seizes Long-Term Immuno-Oncology Opportunity With Merck Deal
Pfizer partnered with Germany’s Merck KGAA to develop and commercialize an anti-PD-L1 checkpoint inhibitor in clinical development, paying $850 million upfront to catch up to the competition.
China’s Regulator Has New Head But Will He Advance Further Reforms?
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Hua Medicine's Chen On Product Launch, Bayer Partnership And Reimbursement
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.